Complete remission in plasma cell leukaemia

C. Montecucco, A. Riccardi, G. Merlini, E. Ascari

Research output: Contribution to journalArticlepeer-review

Abstract

Two patients with primary plasma cell leukaemia who achieved complete remission are reported. They were treated with induction therapy consisting of a multipeptide derivative of sarcolysin, Peptichemio, given intravenously, combined with vincristine and/or prednisone, followed by conventional melphalan-prednisone therapy. 5-7 months following the beginning of therapy, both patients attained a complete remission which lasted 23 and 6 months; second remission was not achieved. Survival from starting therapy was 57 and 16 months respectively. These cases indicate that intravenously alkylating agents can induce a complete remission in plasma cell leukaemia similar to that achieved in other acute leukaemias.

Original languageEnglish
Pages (from-to)525-527
Number of pages3
JournalBritish Journal of Haematology
Volume62
Issue number3
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Complete remission in plasma cell leukaemia'. Together they form a unique fingerprint.

Cite this